Please assess the completion status of the following clinical trial:

Trial Title: ORAL T-6: Oral Androgens in Man-6

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* males between 18 to 50 years of age in good general health based on normal screening evaluation~* must agree not to participate in another research drug study during participation~* must agree to not donate blood during the study~* must be willing to comply with the study protocol and procedures~* must agree to use an acceptable form of contraception~* agrees to not take medications other than the study drugs for the duration of the study~Exclusion Criteria:~* Subject in poor health, determined by medical history physical and lab results~* a known history or current use of alcohol, drug or steroid abuse and/or use of more than 3 alcohol beverages per day~* Participation in a long-term contraceptive study within the past two months~* History of bleeding disorders or current use of anti-coagulants~* History of sleep apnea and/or major psychiatric disorders

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Oral testosterone (Type: EXPERIMENTAL): (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once.
- Finasteride plus Oral Testosterone (Type: EXPERIMENTAL): (Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once.

Based on this trial design, predict the completion outcome and termination type (if applicable).